☰

Debanjan Dhar, Ph.D. - Publications

Affiliations: 
2009 Saint Louis University, St. Louis, MO, United States 
Area:
Molecular Biology, Virology Biology, Immunology
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Experimental Biology and Medicine (Maywood, N.J.). 1535370219898141. PMID 31924111 DOI: 10.1177/1535370219898141  0.327
2019 Nishio T, Hu R, Koyama Y, Liang S, Rosenthal SB, Yamamoto G, Karin D, Baglieri J, Ma HY, Xu J, Liu X, Dhar D, Iwaisako K, Taura K, Brenner DA, et al. Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. Journal of Hepatology. PMID 31071368 DOI: 10.1016/J.Jhep.2019.04.012  0.34
2018 Liang S, Ma HY, Zhong Z, Dhar D, Liu X, Xu J, Koyama Y, Nishio T, Karin D, Karin G, Mccubbin R, Zhang C, Hu R, Yang G, Chen L, et al. NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice. Gastroenterology. PMID 30445007 DOI: 10.1053/J.Gastro.2018.11.019  0.354
2018 Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 33: 1061-1077.e6. PMID 29894692 DOI: 10.1016/J.Ccell.2018.05.003  0.322
2017 Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, et al. Erratum: Inflammation-induced IgA(+) cells dismantle anti-liver cancer immunity. Nature. PMID 29168501 DOI: 10.1038/Nature25028  0.334
2017 Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 551: 340-345. PMID 29144460 DOI: 10.1038/Nature24302  0.363
2016 Karin M, Dhar D. Liver Carcinogenesis: From Naughty Chemicals to Soothing Fat- and the Surprising Role of NRF2. Carcinogenesis. PMID 27207669 DOI: 10.1093/Carcin/Bgw060  0.371
2015 Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 521: 94-8. PMID 25924065 DOI: 10.1038/Nature14395  0.317
2014 Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, Koike K, Kaufman RJ, Karin M. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 26: 331-43. PMID 25132496 DOI: 10.1016/J.Ccr.2014.07.001  0.333
2014 Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A, Kinoshita H, Sakitani K, Nishikawa Y, Hirano K, Ikenoue T, Ijichi H, Dhar D, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 111: 1090-5. PMID 24395807 DOI: 10.1073/Pnas.1322731111  0.325
2013 He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 155: 384-96. PMID 24120137 DOI: 10.1016/J.Cell.2013.09.031  0.34
2012 Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, ... Dhar D, et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Molecular Cell. 45: 171-84. PMID 22196886 DOI: 10.1016/J.Molcel.2011.11.018  0.324
2012 Dhar D, Toth K, Wold WS. Syrian hamster tumor model to study oncolytic Ad5-based vectors. Methods in Molecular Biology (Clifton, N.J.). 797: 53-63. PMID 21948468 DOI: 10.1007/978-1-61779-340-0_4  0.344
2010 Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opinion On Biological Therapy. 10: 353-68. PMID 20132057 DOI: 10.1517/14712590903559822  0.339
2009 Dhar D, Spencer JF, Toth K, Wold WS. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1724-32. PMID 19602998 DOI: 10.1038/Mt.2009.156  0.35
2009 Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WS, Toth K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Therapy. 16: 644-54. PMID 19197324 DOI: 10.1038/Cgt.2009.5  0.351
2009 Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Therapy. 16: 625-37. PMID 19197322 DOI: 10.1038/Cgt.2009.6  0.34
2009 Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. Journal of Virology. 83: 2130-9. PMID 19073718 DOI: 10.1128/Jvi.02127-08  0.345
2008 Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WS. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proceedings of the National Academy of Sciences of the United States of America. 105: 7293-7. PMID 18490659 DOI: 10.1073/Pnas.0800200105  0.306
2006 Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Research. 66: 1270-6. PMID 16452178 DOI: 10.1158/0008-5472.Can-05-3497  0.35
2006 Lichtenstein DL, Toth K, Spencer JF, Meyer J, Ying B, Tollefson AE, Patra D, Shashkova E, Kuppuswamy M, Doronin K, Dhar D, Zumstein LA, Wold WSM. 651. VRX-007, an Oncolytic Adenovirus Vector, Replicates in Syrian Hamsters but Not Mice: Comparison of Biodistribution Studies Performed in the Syrian Hamster and Mouse Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.727  0.351
2006 Toth K, Spencer JF, Lichtenstein DL, Tollefson AE, Patra D, Meyer JM, Shashkova E, Kuppuswamy M, Doronin K, Dhar D, Thomas MA, Zumstein LA, Wold WSM. 642. Toxicological Findings with Oncolytic Adenovirus Vector VRX-007, Wild-Type Ad5, and a Replication-Defective Adenovirus Vector in Syrian Hamsters and C57BL/6 Mice Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.718  0.357
Show low-probability matches.